SB939

SB939 is a novel histone deacetylase (HDAC) inhibitor with improved, pharmaceutical physicochemical, and pharmacokinetic properties. In vitro, this substance inhibits class I, II, and IV HDACs, with no effects on other zinc binding enzymes, and shows significant antiproliferative activity against a wide variety of tumor cell lines. It has very favorable pharmacokinetic properties after oral dosing in mice, with >4-fold increased bioavailability and 3.3-fold increased half-life over SAHA (Suberoylanilide Hydroxamic Acid).

Synonyms: SB-939; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide
Technical Data: Molecular Weight - 358.49; Molecular formula - C20H30N4O2; CAS No - 929016-96-6

Ordering Information: Product Number - EC-000.2481; Price and Availability: Inquire This product is also available to buy in bulk quantities.

Related Products: Suberoylanilide Hydroxamic Acid; MS-275 (Entinostat); CI-994 (Tacedinaline); BML-210; M344; MGCD0103 (Mocetinostat); PXD101 (Belinostat); LBH-589 (Panobinostat); Tubastatin A; Scriptaid; NSC 3852; NCH 51; HNHA; BML-281; CBHA; Salermide; Pimelic Diphenylamide; ITF2357 (Givinostat); PCI-24781; APHA Compound 8; Droxinostat.

References:
1. Veronica Novotny-Diermayr, Kanda Sangthongpitag, Chang Yong Hu, et al. SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer. Mol Cancer Ther. March 2010 9; 642.